{"id":479519,"date":"2021-04-21T08:05:55","date_gmt":"2021-04-21T12:05:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/"},"modified":"2021-04-21T08:05:55","modified_gmt":"2021-04-21T12:05:55","slug":"inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/","title":{"rendered":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ATLANTA<\/span>, <span class=\"xn-chron\">April 21, 2021<\/span> \/PRNewswire\/ &#8212; Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson&#8217;s disease and related disorders inside and outside of the brain, today announced that <span class=\"xn-person\">Milton Werner<\/span>, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009&#8217;s mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on <span class=\"xn-chron\">April 28-30, 2021<\/span>. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg\" title=\"Inhibikase Therapeutics, Inc. Logo (PRNewsfoto\/Inhibikase Therapeutics, Inc.)\" alt=\"Inhibikase Therapeutics, Inc. Logo (PRNewsfoto\/Inhibikase Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson&#8217;s &amp; Movement Disorders panel discussion on <span class=\"xn-chron\">Wednesday, April 28<\/span><sup>th<\/sup>, at <span class=\"xn-chron\">1:20 p.m. ET<\/span>. In addition, Dr. Werner will separately present a corporate overview of Inhibikase.<\/p>\n<p>\n        <b>About Inhibikase (<\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3136150-1&amp;h=2324116515&amp;u=http%3A%2F%2Fwww.inhibikase.com%2F&amp;a=www.inhibikase.com\" rel=\"nofollow noopener\">www.inhibikase.com<\/a><br \/>\n        <b>) <\/b>\n      <\/p>\n<p>Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson&#8217;s\u00a0disease and related disorders. Inhibikase&#8217;s\u00a0multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson&#8217;s\u00a0disease inside and outside the brain. Inhibikase is currently performing\u00a0its Phase I, randomized single ascending dose and multiple ascending dose,\u00a0study to determine the safety, tolerability and pharmacokinetics of IkT-148009\u00a0in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in <span class=\"xn-location\">Atlanta, Georgia<\/span> with offices in <span class=\"xn-location\">Boston, Massachusetts<\/span>.<\/p>\n<p>\n        <b>Social Media Disclaimer<\/b>\n      <\/p>\n<p>Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3136150-1&amp;h=195159588&amp;u=https%3A%2F%2Ftwitter.com%2Finhibikase&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3136150-1&amp;h=2991349411&amp;u=https%3A%2F%2Fwww.facebook.com%2FInhibikase&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3136150-1&amp;h=362295446&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finhibikase-therapeutics%2F&amp;a=LinkedIn\" rel=\"nofollow noopener\">LinkedIn<\/a>\u00a0and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3136150-1&amp;h=1064632864&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FInhibikase&amp;a=YouTube\" rel=\"nofollow noopener\">YouTube<\/a>\u00a0as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase&#8217;s\u00a0current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase&#8217;s\u00a0actual results to differ materially from those anticipated by the forward-looking statements.\u00a0One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates.\u00a0Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase&#8217;s\u00a0filings with the SEC, including its annual report\u00a0on Form 10-K filed on <span class=\"xn-chron\">March 31<\/span>, 2021,\u00a0including under the caption &#8220;Risk Factors.&#8221;\u00a0Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CL49902&amp;sd=2021-04-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum-301273319.html\">http:\/\/www.prnewswire.com\/news-releases\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum-301273319.html<\/a><\/p>\n<p>SOURCE  Inhibikase Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CL49902&amp;Transmission_Id=202104210800PR_NEWS_USPR_____CL49902&amp;DateId=20210421\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ATLANTA, April 21, 2021 \/PRNewswire\/ &#8212; Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson&#8217;s disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009&#8217;s mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021. Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson&#8217;s &amp; Movement Disorders panel discussion on Wednesday, April 28th, at 1:20 p.m. ET. In addition, Dr. Werner will separately present a corporate overview of Inhibikase. About Inhibikase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479519","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ATLANTA, April 21, 2021 \/PRNewswire\/ &#8212; Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson&#8217;s disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009&#8217;s mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021. Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson&#8217;s &amp; Movement Disorders panel discussion on Wednesday, April 28th, at 1:20 p.m. ET. In addition, Dr. Werner will separately present a corporate overview of Inhibikase. About Inhibikase &hellip; Continue reading &quot;Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:05:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum\",\"datePublished\":\"2021-04-21T12:05:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/\"},\"wordCount\":551,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1441491\\\/IKT_Logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/\",\"name\":\"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1441491\\\/IKT_Logo_Logo.jpg\",\"datePublished\":\"2021-04-21T12:05:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1441491\\\/IKT_Logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1441491\\\/IKT_Logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/","og_locale":"en_US","og_type":"article","og_title":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk","og_description":"PR Newswire ATLANTA, April 21, 2021 \/PRNewswire\/ &#8212; Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson&#8217;s disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009&#8217;s mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021. Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson&#8217;s &amp; Movement Disorders panel discussion on Wednesday, April 28th, at 1:20 p.m. ET. In addition, Dr. Werner will separately present a corporate overview of Inhibikase. About Inhibikase &hellip; Continue reading \"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:05:55+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum","datePublished":"2021-04-21T12:05:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/"},"wordCount":551,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/","name":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg","datePublished":"2021-04-21T12:05:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1441491\/IKT_Logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479519"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}